Advanced search
1 file | 436.44 KB Add to list

Serum HE4 is correlated to prognostic factors and survival in patients with endometrial cancer

(2017) VIRCHOWS ARCHIV. 470(6). p.655-664
Author
Organization
Abstract
The extent of surgery and the decision for adjuvant treatment in patients with endometrial cancer (EC) depend on the presence of risk factors for lymph node metastases and disease recurrence. Postoperative markers such as myometrial infiltration and specific mutations can select patients for adjuvant treatment but will not influence surgical planning. A biomarker stratifying patients into low-risk and high-risk groups before surgery could identify patients who benefit from more extensive surgery. Therefore, we evaluated the correlation of serum biomarker HE4 with clinical and recently identified prognostic pathological variables and survival. Patients treated for endometrial cancer between 1994 and 2014 were included. Serum HE4 concentration was measured in preoperatively obtained samples. A total of 88 patients were eligible for analysis. The majority (64%) was diagnosed with endometrioid-type adenocarcinoma. Serum HE4 concentration is significantly associated with stage of disease (p = 0.001), deep myometrial invasion (p < 0.001), exact depth of myometrial invasion (>= 4 mm) (p = 0.01), tumour-free distance to serosa (<= 7 mm) (p < 0.001), extensive lymph vascular space invasion (p = 0.04) and cervical involvement (p = 0.001). HE4 concentration and nodal involvement were correlated, although not significant (p = 0.17). Serum HE4 is an independent prognostic factor for recurrence-free survival (HR 5.12 per 10-fold increase in HE4, 95% CI 1.54-17.1) and overall survival (HR 7.48 per 10-fold increase in HE4, 95% CI 1.76-31.7). HE4 is a prognostic marker in endometrial cancer and is helpful in addition to other variables for the preoperative risk stratification of patients with endometrial cancer.
Keywords
Endometrial cancer, SerumHE4, Myometrial invasion, Prognosis, LYMPHOVASCULAR SPACE INVASION, SENTINEL-NODE BIOPSY, MYOMETRIAL INVASION, CARCINOMA, STAGE, MARKER, IMPACT, ADENOCARCINOMA, CLASSIFICATION, METAANALYSIS

Downloads

  • (...).pdf
    • full text
    • |
    • UGent only
    • |
    • PDF
    • |
    • 436.44 KB

Citation

Please use this url to cite or link to this publication:

MLA
Stiekema, A, CAR Lok, CM Korse, et al. “Serum HE4 Is Correlated to Prognostic Factors and Survival in Patients with Endometrial Cancer.” VIRCHOWS ARCHIV 470.6 (2017): 655–664. Print.
APA
Stiekema, A, Lok, C., Korse, C., van Driel, W., van der Noort, V., Kenter, G., & Van de Vijver, K. (2017). Serum HE4 is correlated to prognostic factors and survival in patients with endometrial cancer. VIRCHOWS ARCHIV, 470(6), 655–664.
Chicago author-date
Stiekema, A, CAR Lok, CM Korse, WJ van Driel, V van der Noort, GG Kenter, and Koen Van de Vijver. 2017. “Serum HE4 Is Correlated to Prognostic Factors and Survival in Patients with Endometrial Cancer.” Virchows Archiv 470 (6): 655–664.
Chicago author-date (all authors)
Stiekema, A, CAR Lok, CM Korse, WJ van Driel, V van der Noort, GG Kenter, and Koen Van de Vijver. 2017. “Serum HE4 Is Correlated to Prognostic Factors and Survival in Patients with Endometrial Cancer.” Virchows Archiv 470 (6): 655–664.
Vancouver
1.
Stiekema A, Lok C, Korse C, van Driel W, van der Noort V, Kenter G, et al. Serum HE4 is correlated to prognostic factors and survival in patients with endometrial cancer. VIRCHOWS ARCHIV. 2017;470(6):655–64.
IEEE
[1]
A. Stiekema et al., “Serum HE4 is correlated to prognostic factors and survival in patients with endometrial cancer,” VIRCHOWS ARCHIV, vol. 470, no. 6, pp. 655–664, 2017.
@article{8578018,
  abstract     = {The extent of surgery and the decision for adjuvant treatment in patients with endometrial cancer (EC) depend on the presence of risk factors for lymph node metastases and disease recurrence. Postoperative markers such as myometrial infiltration and specific mutations can select patients for adjuvant treatment but will not influence surgical planning. A biomarker stratifying patients into low-risk and high-risk groups before surgery could identify patients who benefit from more extensive surgery. Therefore, we evaluated the correlation of serum biomarker HE4 with clinical and recently identified prognostic pathological variables and survival. Patients treated for endometrial cancer between 1994 and 2014 were included. Serum HE4 concentration was measured in preoperatively obtained samples. A total of 88 patients were eligible for analysis. The majority (64%) was diagnosed with endometrioid-type adenocarcinoma. Serum HE4 concentration is significantly associated with stage of disease (p = 0.001), deep myometrial invasion (p < 0.001), exact depth of myometrial invasion (>= 4 mm) (p = 0.01), tumour-free distance to serosa (<= 7 mm) (p < 0.001), extensive lymph vascular space invasion (p = 0.04) and cervical involvement (p = 0.001). HE4 concentration and nodal involvement were correlated, although not significant (p = 0.17). Serum HE4 is an independent prognostic factor for recurrence-free survival (HR 5.12 per 10-fold increase in HE4, 95% CI 1.54-17.1) and overall survival (HR 7.48 per 10-fold increase in HE4, 95% CI 1.76-31.7). HE4 is a prognostic marker in endometrial cancer and is helpful in addition to other variables for the preoperative risk stratification of patients with endometrial cancer.},
  author       = {Stiekema, A and Lok, CAR and Korse, CM and van Driel, WJ and van der Noort, V and Kenter, GG and Van de Vijver, Koen},
  issn         = {0945-6317},
  journal      = {VIRCHOWS ARCHIV},
  keywords     = {Endometrial cancer,SerumHE4,Myometrial invasion,Prognosis,LYMPHOVASCULAR SPACE INVASION,SENTINEL-NODE BIOPSY,MYOMETRIAL INVASION,CARCINOMA,STAGE,MARKER,IMPACT,ADENOCARCINOMA,CLASSIFICATION,METAANALYSIS},
  language     = {eng},
  number       = {6},
  pages        = {655--664},
  title        = {Serum HE4 is correlated to prognostic factors and survival in patients with endometrial cancer},
  url          = {http://dx.doi.org/10.1007/s00428-017-2115-1},
  volume       = {470},
  year         = {2017},
}

Altmetric
View in Altmetric
Web of Science
Times cited: